|
May 7
|
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
|
|
May 6
|
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 6
|
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
|
|
Aug 22
|
Lyra Therapeutics Insiders Still US$66k Away From Original Investment Value
|
|
May 7
|
Target upgraded, CVS downgraded: Wall Street's top analyst calls
|
|
May 6
|
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
|
|
May 2
|
Lyra Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Apr 30
|
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
|
|
Apr 30
|
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Apr 26
|
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 28
|
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
|
|
Mar 26
|
Private equity firms who hold 39% of Lyra Therapeutics, Inc. (NASDAQ:LYRA) gained 6.8%, institutions profited as well
|
|
Mar 25
|
Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
|
|
Mar 23
|
Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections
|
|
Mar 22
|
Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
|
|
Mar 21
|
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 8
|
Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going
|
|
Mar 1
|
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 1
|
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
|
|
Feb 29
|
5 Small Drug Stocks to Buy From a Rebounding Industry
|